Karyopharm Therapeutics Inc Q3 2024 Everything You Need To Know Ahead Of Earnings
KPTI Stock | USD 0.59 0.01 0.83% |
Under 67% of Karyopharm Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Karyopharm Therapeutics suggests that many traders are alarmed. Karyopharm Therapeutics' investing sentiment shows overall attitude of investors towards Karyopharm Therapeutics.
Karyopharm |
Karyopharm Therapeutics Inc is set to release its Q3 2024 earnings on Nov 5, 2024. The consensus estimate for Q3 2024 revenue is 37.79 million, and the earnings are expected to come in at -0.26 per share. The full year 2024s revenue is expected to be 152.35 million and the earnings are expected to be -0.68 per share.
Read at finance.yahoo.com
Karyopharm Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Karyopharm Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Karyopharm Therapeutics Fundamental Analysis
We analyze Karyopharm Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karyopharm Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karyopharm Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Karyopharm Therapeutics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Karyopharm Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Karyopharm Therapeutics stock to make a market-neutral strategy. Peer analysis of Karyopharm Therapeutics could also be used in its relative valuation, which is a method of valuing Karyopharm Therapeutics by comparing valuation metrics with similar companies.
Peers
Karyopharm Therapeutics Related Equities
XFOR | X4 Pharmaceuticals | 39.66 | ||||
BLUE | Bluebird Bio | 12.71 | ||||
NVCT | Nuvectis Pharma | 9.25 | ||||
RLYB | Rallybio Corp | 6.98 | ||||
LYRA | Lyra Therapeutics | 5.88 | ||||
CTMX | CytomX Therapeutics | 5.61 | ||||
ABOS | Acumen Pharmaceuticals | 5.59 | ||||
ASMB | Assembly Biosciences | 4.48 | ||||
GBIO | Generation Bio | 3.74 | ||||
GLUE | Monte Rosa | 2.41 | ||||
REPL | Replimune | 2.32 | ||||
GOSS | Gossamer Bio | 1.19 | ||||
AGIO | Agios Pharm | 0.53 | ||||
NUVB | Nuvation Bio | 0.00 | ||||
PMVP | Pmv Pharmaceuticals | 0.00 | ||||
MREO | Mereo BioPharma | 1.31 | ||||
HOOK | Hookipa Pharma | 2.63 | ||||
KRON | Kronos Bio | 3.16 | ||||
MRSN | Mersana Therapeutics | 12.35 |
Complementary Tools for Karyopharm Stock analysis
When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Global Correlations Find global opportunities by holding instruments from different markets | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |